A randomized controlled trial of adjunctive erythromycin in women with idiopathic preterm labor.

Author(s): Rajaei M, Sultani M, Zare S

Affiliation(s): Department of Obstetrics and Gynecology, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. rajaei_minoo@yahoo.com

Publication date & source: 2006-01, J Matern Fetal Neonatal Med., 19(1):17-20.

Publication type: Randomized Controlled Trial

OBJECTIVE: Our purpose was to determine the effects of erythromycin among hospitalized women with idiopathic preterm labor who were treated with tocolytics. METHODS: This prospective randomized trial was conducted in patients with preterm labor of no clinically identifiable cause between 26 and 34 weeks of gestation, who were receiving magnesium sulfate. A total of 136 patients were screened. Of these, 80 eligible, consenting patients were randomized to receive either 400 mg erythromycin or placebo orally every 6 hours for 10 days. Necessary statistical comparisons were preformed using unpaired two-tailed Student's t-test and Chi-square analysis. RESULTS: In comparing the 38 erythromycin and 42 placebo patients there was improvement in the treatment-to-delivery interval (33.33 +/- 18.36 versus 26.88 +/- 13.9 days, respectively), mean gestational age at delivery (36.11 +/- 2.33 versus 34.36 +/- 2.33 weeks, respectively), mean birth weight (2722.31 +/- 511.65 versus 2419.41 +/- 513.54 g, respectively), and reduced neonatal admission to NICU (36.8% versus 60.19%) in the erythromycin group. CONCLUSION: In patients with idiopathic preterm labor the adjunctive use of erythromycin therapy appeared safe and well tolerated and resulted in a statistically significant delay from admission to delivery and improved gestational age at delivery, mean birth weight and neonatal outcome.